UNASSIGNED: From January 2013 to December 2021, the study included 179 EAU intermediate-risk patients presenting with an unfavorable tumor grade (ISUP 3), eventually associated with a PSA of 10-20 ng/ml and/or cT-2b. Briganti\'s 2012 nomogram was assessed as both a continuous and dichotomous variable, categorized according to the median (risk score ⩾7% vs <7%). Disease progression, defined as biochemical recurrence and/or metastatic progression, was evaluated using Cox proportional hazards in both univariate and multivariate analyses.
UNASSIGNED: Disease progression occurred in 43 (24%) patients after a median (95% CI) follow-up of 78 (65.7-88.4) months. The nomogram risk score predicted disease progression, evaluated both as a continuous variable (hazard ratio, HR = 1.064; 95% CI: 1.035-1.093; p < 0.0001) and as a categorical variable (HR = 3.399; 95% CI: 1.740-6.638; p < 0.0001). This association was confirmed in multivariate analysis, where hazard ratios remained consistent even after adjusting for clinical and pathological factors.
UNASSIGNED: In EAU intermediate-risk PCa cases presenting with an unfavorable tumor grade and treated surgically, Briganti\'s 2012 nomogram was associated with disease progression after surgery. Consequently, as the nomogram risk score increased, patients were more likely to experience PCa progression, facilitating the stratification of the patient population into distinct prognostic subgroups.
■从2013年1月到2021年12月,该研究包括179名EAU中危患者,表现为不良肿瘤等级(ISUP3),最终与PSA为10-20ng/ml和/或cT-2b相关。Briganti的2012列线图被评估为连续变量和二分变量,根据中位数进行分类(风险评分为7%vs<7%)。疾病进展,定义为生化复发和/或转移性进展,在单变量和多变量分析中使用Cox比例风险进行评估。
■在中位(95%CI)随访78(65.7-88.4)个月后,43例(24%)患者出现疾病进展。列线图风险评分预测疾病进展,两者都被评估为连续变量(风险比,HR=1.064;95%CI:1.035-1.093;p<0.0001),作为分类变量(HR=3.399;95%CI:1.740-6.638;p<0.0001)。这种关联在多变量分析中得到证实,即使在调整了临床和病理因素后,风险比仍然保持一致。
■在EAU中危PCa病例中,表现为不良肿瘤等级并接受手术治疗,Briganti2012年列线图与手术后疾病进展相关。因此,随着列线图风险评分的增加,患者更有可能经历PCa进展,促进将患者群体分层为不同的预后亚组。